Kimmig R, Kapsner T, Spelsberg H, Untch M, Hepp H
Department of Obstetrics and Gynecology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Germany.
J Cancer Res Clin Oncol. 1995;121(2):107-14. doi: 10.1007/BF01202222.
DNA ploidy and cell-cycle distribution were determined by flow cytometry in fresh tumour tissue of 53 cervical carcinomas. Epithelial cells were labelled by a fluorescein-isothiocyanate-conjugated cytokeratin antibody (CK6, CK18) to study the influence of contaminating stromal and inflammatory cells on results of cell-cycle analysis of tumour cells. Without identification of cytokeratin-positive cells 30/53 (57%) tumours were found to be DNA-aneuploid compared to 43/53 (81%) after gating for cytokeratin. Only 7 of 15 DNA-multiploid tumours could be detected without cytokeratin staining. In addition, cytokeratin-negative cells, which are found in all tumours, can be used as an internal standard for the calculation of ploidy and for quality control (coefficient of variation, linearity) of each individual sample. Cell-cycle analysis revealed significantly higher S-phase and G2M-phase fractions in cytokeratin-gated compared to ungated samples (13.1% versus 10.0% and 8.0% versus 5.4%; P < 0.001). This difference was more pronounced in DNA-diploid than DNA-aneuploid tumours. In conclusion, about 30% of DNA-aneuploid tumours could only be detected after cytokeratin labelling of epithelial cells. Owing to the identification of cytokeratin-positive cells the influence of non-tumoural cell elements on cell-cycle analysis was reduced markedly. Therefore, in cervical cancer, cytokeratin labelling can optimize both the determination of DNA ploidy and cell-cycle analysis.
采用流式细胞术对53例宫颈癌新鲜肿瘤组织进行DNA倍体和细胞周期分布测定。用异硫氰酸荧光素偶联的细胞角蛋白抗体(CK6、CK18)标记上皮细胞,以研究污染的基质细胞和炎性细胞对肿瘤细胞周期分析结果的影响。未识别细胞角蛋白阳性细胞时,53例肿瘤中有30例(57%)被发现为DNA非整倍体,而在对细胞角蛋白进行门控后,这一比例为43/53(81%)。在未进行细胞角蛋白染色的情况下,15例DNA多倍体肿瘤中仅7例可被检测到。此外,在所有肿瘤中均发现的细胞角蛋白阴性细胞可作为计算倍体的内标以及每个样本的质量控制(变异系数、线性度)标准。细胞周期分析显示,与未进行门控的样本相比,经细胞角蛋白门控的样本中S期和G2M期比例显著更高(分别为13.1%对10.0%以及8.0%对5.4%;P<0.001)。这种差异在DNA二倍体肿瘤中比在DNA非整倍体肿瘤中更为明显。总之,约30%的DNA非整倍体肿瘤仅在对上皮细胞进行细胞角蛋白标记后才能被检测到。由于识别了细胞角蛋白阳性细胞,非肿瘤细胞成分对细胞周期分析的影响显著降低。因此,在宫颈癌中,细胞角蛋白标记可优化DNA倍体的测定和细胞周期分析。